WO2008037037A3 - Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc. - Google Patents
Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc. Download PDFInfo
- Publication number
- WO2008037037A3 WO2008037037A3 PCT/BG2007/000021 BG2007000021W WO2008037037A3 WO 2008037037 A3 WO2008037037 A3 WO 2008037037A3 BG 2007000021 W BG2007000021 W BG 2007000021W WO 2008037037 A3 WO2008037037 A3 WO 2008037037A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- asthmatic
- medicine
- hydrochloricum
- sulfuricum
- sulfaguajacolicum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The anti-asthmatic medicine can be implemented in the field o the human medicine for a treatment of the bronchial asthma and the asthmatic bronchitis. The medicine contains coffeinum purum, ergotamintartarat, zincum sulfuricum papaverinum hydrochloricum, atropinum sulfuricum, aminophyllinum, glaucinum hydrochloricum, kalium sulfaguajacolicum and chlorpyraminum, having quantity proportions [in mgj: coffeinum paru 30,00 to 250,00;' ergotamintartarat 0,25 to 2,00; zincum sulfuricum10,00 to 400,00; papaverinum hydrochloricum 30,00 to 200,00; atropinum sulfuricum 0,25 to 1,00; aminophyllinum 40,00 to 250,00;glaucinum hydrochloricum 30,00 to 250,00; kalium sulfaguajacolicum 100,00 to 600,00; chlorpyraminum 30,00 to 200,00. The medicine has a number of advangates, as follows: even the acutest asthmatic ebullitions are being put under control in the course of 30-40 minutes; prevented is a new appearance of a painful asthmatic respiration and of consequent asthmatic ebullitions for periods of 10-20 and more vears i.e. in practice a treatment of the disease is achieved; prevented are the acute side effects and complications of the corticosteroids; the medicinbe has a good bearing and does not result in complications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG109687A BG109687A (en) | 2006-09-26 | 2006-09-26 | Antiasthmatic drug |
| BG109687 | 2006-09-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008037037A2 WO2008037037A2 (en) | 2008-04-03 |
| WO2008037037A3 true WO2008037037A3 (en) | 2008-07-10 |
Family
ID=39060181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BG2007/000021 Ceased WO2008037037A2 (en) | 2006-09-26 | 2007-09-19 | Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc. |
Country Status (2)
| Country | Link |
|---|---|
| BG (1) | BG109687A (en) |
| WO (1) | WO2008037037A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113633710A (en) * | 2021-09-29 | 2021-11-12 | 浙江养和健康管理科技有限公司 | A Chinese medicinal composition for treating bronchitis, asthma and emphysema, and its preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031222A1 (en) * | 1994-03-23 | 1996-10-10 | Ivan Dimitrov Hristov | Antiasthmatic preparation |
| US20010010825A1 (en) * | 1998-07-28 | 2001-08-02 | Toshihiro Shimizu | Rapidly disintegrable solid preparation |
| BG105687U (en) * | 2001-07-10 | 2003-01-31 | "Софарма" Ад | Combined means for affecting the respiratory system |
-
2006
- 2006-09-26 BG BG109687A patent/BG109687A/en unknown
-
2007
- 2007-09-19 WO PCT/BG2007/000021 patent/WO2008037037A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031222A1 (en) * | 1994-03-23 | 1996-10-10 | Ivan Dimitrov Hristov | Antiasthmatic preparation |
| US20010010825A1 (en) * | 1998-07-28 | 2001-08-02 | Toshihiro Shimizu | Rapidly disintegrable solid preparation |
| BG105687U (en) * | 2001-07-10 | 2003-01-31 | "Софарма" Ад | Combined means for affecting the respiratory system |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002478408 * |
| SZEMERE P A ET AL: "Consumption of antihistamines and antiasthmatics in Hungary during 1992-1996", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 118, no. 2-4, February 1999 (1999-02-01), pages 335 - 337, XP009096574, ISSN: 1018-2438 * |
| WAN HUAN-YING ET AL: "Effect of theophylline and glucose injection in treating acute asthma", ZHONGGUO XINYAO YU LINCHUANG ZAZHI, vol. 23, no. 3, March 2004 (2004-03-01), pages 159 - 163, XP002470608, ISSN: 1007-7669 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008037037A2 (en) | 2008-04-03 |
| BG109687A (en) | 2008-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005099715A3 (en) | Treatment of ophthalmic conditions with mineralcorticoids | |
| AU6918700A (en) | Pharmaceutical compositions and methods for reducing the appearance of cellulite | |
| WO2007133816A3 (en) | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists | |
| CN102002767A (en) | Pearl-traditional Chinese medicine fiber with functions of skin care and health care and preparation method thereof | |
| WO2009079451A3 (en) | Compositions and methods of promoting wound healing | |
| EP2759302A3 (en) | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | |
| CN101926393A (en) | Cordyceps sinensis health-care edible oil | |
| CN106726782A (en) | One plant tea massage oil and preparation method and application | |
| CN101427844A (en) | Health care cigarette of fig | |
| WO2008037037A3 (en) | Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc. | |
| CN101584651A (en) | A kind of pearl skin-care product | |
| CN102755507B (en) | A kind of traditional Chinese herbal decoction for the treatment of wind-dryness impariment of the lung type acute bronchitis | |
| KR20130142326A (en) | Composition for hair growth | |
| CN101185722B (en) | Infusion medicine for treating beriberi | |
| CN202197887U (en) | Gloves for preventing and treating chilblain | |
| CN105639588A (en) | Health-care yellow salt and preparation method thereof | |
| CN104005254A (en) | Tipping base paper capable of clearing heat and alleviating hangover and preparation method thereof | |
| CN102370665A (en) | Traditional Chinese medicinal composition and method for treating sweating of children | |
| CN101455685A (en) | Navel patch for treating infantile cold sweat syndrome | |
| CN2796427Y (en) | Protecting and treating sleeve for heel rhagadia | |
| CN101062090A (en) | Method for preparing the agent for relieving the pain of cancer patients | |
| CN101199703A (en) | Tincture medicament for treating acne | |
| CN1243729A (en) | Medicine for treating corn | |
| CN101467794A (en) | Novel use of mint oil | |
| CN105687166A (en) | Deodorization foot patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07815698 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07815698 Country of ref document: EP Kind code of ref document: A2 |